Verseon Gain US Patent Protection for Compounds that Could Eliminate Bleeding Risks of Current Anticoagulants

Verseon Gain US Patent Protection for Compounds that Could Eliminate Bleeding Risks of Current Anticoagulants

“They could radically improve the standard of care for several hundred million underserved patients around the world,” says Verseon’s CSO David Kita

Fremont, Calif.— Verseon is pleased to announce that the USPTO has granted a new patent entitled “Thrombin Inhibitors, Formulations, and Uses Thereof,” further extending intellectual property protection for Verseon’s novel class of thrombin inhibitors. These anticoagulant compounds promise to open new and safer treatment options for the world’s 400+ million cardiovascular disease patients.

Patients with cardiovascular disease are often at risk of strokes and heart attacks and would benefit from lifelong use of an anticoagulant, either alone or in combination with an antiplatelet drug. Unfortunately, the bleeding risk posed by all anticoagulants currently on the market is exceedingly high when these drugs are used by themselves – and entirely unacceptable when used together with blood-thinning antiplatelet drugs.

Unlike current anticoagulants, Verseon’s Precision Oral Anticoagulants (PROACs) covered by this patent exhibit a fundamentally novel mechanism of action that does not increase the risk of bleeding yet prevents the formation of the dangerous blood clots behind heart attacks and strokes. Because these compounds are also exquisitely selective against other structurally similar protein targets, they are expected to cause far fewer side effects. Further, their unique mechanism of action does not inhibit platelet activation, making them well suited for long-term use with antiplatelet drugs.

“We are pleased by the USPTO’s decision to grant additional patent protection for our novel compounds,” said Verseon’s CSO David Kita. “They could radically improve the standard of care for several hundred million underserved patients around the world.”

Verseon’s scientists consistently find unique drug candidates that have never been designed or synthesized before. The company’s breakthroughs in physics- and AI-driven molecule engineering allow them to chart previously unexplored parts of chemical space – and create new drug candidates with unique treatment profiles that promise to change the standard of care for every drug program the company undertakes.

About Verseon

Verseon International Corporation (www.verseon.com) is transforming the delay, prevention, and treatment of disease. Using its Deep Quantum Models + AI platform, Verseon is rolling out a steady stream of life-changing medicines. Each of the company’s drug programs features multiple novel candidates with unique therapeutic properties. None of these candidates can be found by other current methods. Verseon’s fast-growing pipeline addresses major human diseases in the areas of cardiometabolic disorders and cancers.